Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Eli-Lilly"

67 News Found

Melissa Seymour to join Lilly as executive vice president of Global Quality
People | June 06, 2024

Melissa Seymour to join Lilly as executive vice president of Global Quality

Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry


Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
News | May 29, 2024

Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history


Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
News | May 01, 2024

Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion

2024 full-year revenue guidance raised by US$ 2 billion


Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg
Drug Approval | April 10, 2024

Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac Tablets of Eli Lilly


Lily announces positive gene therapy result for genetic hearing loss
Diagnostic Center | January 25, 2024

Lily announces positive gene therapy result for genetic hearing loss

Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant


BioAsia 2024 to focus on data and AI for life sciences
News | January 11, 2024

BioAsia 2024 to focus on data and AI for life sciences

The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others


Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China
Diagnostic Center | December 28, 2023

Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China

Innovent will supply sintilimab for the collaborated clinical trial


Zepbound is now available in US for adults living with obesity
News | December 09, 2023

Zepbound is now available in US for adults living with obesity

Express Scripts to add Zepbound to National Preferred Formulary


Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer
News | October 26, 2023

Lilly's Retevmo phase 3 results in RET fusion-positive non-small cell lung cancer

In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)


Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData
News | July 29, 2023

Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData

In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1